Alnylam Pharmaceuticals (ALNY) closed at $155.94 on November 6, 2026, down 0.5% from the previous close, on volume of 2,538,062 shares (30-day average 2,124,597).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 2, 2026 | Call Spread | 15-Jan-27150 : 160 C | 1,074 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Cantor Fitzgerald Remains a Hold on Alnylam Pharma (ALNY)
TipRanks (Fri, 6-Nov 2:39 PM ET)
Alnylam’s Amvuttra Growth Potential Supports Buy Rating Despite 340B Risks
TipRanks (Thu, 5-Nov 5:55 PM ET)
Analysts Are Bullish on Top Healthcare Stocks: Schrodinger (SDGR), Alnylam Pharma (ALNY)
TipRanks (Thu, 5-Nov 8:30 AM ET)
TipRanks (Thu, 5-Nov 8:20 AM ET)
Alnylam Pharma Announces Chief Commercialization Officer Departure
TipRanks (Thu, 5-Nov 8:17 AM ET)
Piper Sandler Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
TipRanks (Thu, 5-Nov 7:29 AM ET)
H.C. Wainwright Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
TipRanks (Thu, 5-Nov 6:36 AM ET)
TipRanks (Thu, 5-Nov 6:10 AM ET)
Alnylam Pharmaceuticals authorizes $1B share repurchase program
Seeking Alpha News (Wed, 4-Nov 5:21 PM ET)
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
Business Wire (Wed, 4-Nov 5:15 PM ET)
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Alnylam Pharmaceuticals trades on the NASDAQ stock market under the symbol ALNY.
As of November 6, 2026, ALNY stock price declined to $155.94 with 2,538,062 million shares trading.
ALNY has a beta of 0.80, meaning it tends to be less sensitive to market movements. ALNY has a correlation of 0.03 to the broad based SPY ETF.
ALNY has a market cap of $20.87 billion. This is considered a Large Cap stock.
Last quarter Alnylam Pharmaceuticals reported $1 billion in Revenue and $16.26 earnings per share. This beat revenue expectation by $25 million and exceeded earnings estimates by $14.17.
In the last 3 years, ALNY traded as high as $495.55 and as low as $141.98.
The top ETF exchange traded funds that ALNY belongs to (by Net Assets): VTI, VO, QQQ, VUG, VXF.
ALNY has underperformed the market in the last year with a price return of -64.6% while the SPY ETF gained +10.8%. ALNY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -27.8% and -30.4%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
ALNY support price is $151.63 and resistance is $161.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALNY shares will trade within this expected range on the day.
